Induction of interleukin-8 (IL-8) by IL-1 or tumor necrosis factor (TNF), and repression by interferons or glucocorticoids have been shown to involve sequences between nucleotides −94 and −71 of the 5′-flanking region, and the transcription factors NF-IL-6 and NF-κB. The A3 cell line was derived from the human melanoma cell line G-361 by stable transfection with part of the IL-8 promoter (nucleotides −101 to +40 from transcription start) fused to the luciferase coding region. These regulatory sequences were sufficient for transcriptional activation by all-trans-retinoic acid (ATRA), 9-cis-retinoic acid, IL-1β, or TNF-α. Simultaneous treatment of A3 cells with ATRA and TNF-α resulted in a dose- and time-dependent synergistic increase in luciferase expression and IL-8 mRNA levels. Transient transfections of the parental cell line demonstrated that the NF-κB binding site is essential for this synergistic transactivation. Electrophoretic mobility shift assays with nuclear extracts of A3 cells showed that stimulation with ATRA and TNF-α for more than 16 h resulted in enhanced NF-κB binding compared to that induced by TNF-α alone. The simultaneous treatment with ATRA and TNF-α also resulted in changes in the composition of NF-κB complexes bound to the IL-8 NF-κB site, preventing the formation of two TNF-α-inducible binding activities. We suggest that these complexes consist of repressive factors which, when removed, allow enhanced binding of NF-κB to its cognate site.
1 November 1997 in European Journal of Biochemistry
Regulation of interleukin‐8 (IL‐8) gene transcription occurs mainly through the sequences ‐94 to ‐71 of the 5′‐flanking region of the IL‐8 gene, involving the transcription factors nuclear factor for interleukin‐6 (NF‐IL‐6) and nuclear factor κB (NF‐κB). The human melanoma cell line A3 was derived from G‐361 cells by stable transfection with an IL‐8 promoter–luciferase construct containing these sequences. 1α,25‐Dihydroxyvitamin D3 (calcitriol) repressed IL‐8 promoter activity induced by tumor necrosis factor‐α (TNF‐α) by 50%, compared to 30% inhibition using dexamethasone, an effect consistent with its effect on TNF‐α‐induced IL‐8 release and IL‐8 mRNA levels. A variety of vitamin D metabolites caused the same repressive effect on IL‐8 promoter activation as calcitriol. However, only those metabolites which were able to transactivate a classical vitamin D response element had the ability to repress IL‐8 promoter activation, suggesting that this repression is mediated via vitamin D receptor (VDR). Furthermore, overexpression of VDR in the parental G‐361 cell line enhanced the repressive effect of calcitriol on activation of the IL‐8 promoter by either TNF‐α stimulation or overexpression of the NF‐κB subunit p65. Electrophoretic mobility shift assays using nuclear extracts from A3 cells showed that calcitriol decreased the abundance of nuclear factors bound to the NF‐κB binding site of the IL‐8 promoter and this reduced binding of NF‐κB proteins presumably contributes to its inhibitory action.
Plasminogen activator inhibitor 1 (PAI-1) is the main fibrinolysis inhibitor, and high plasma levels are associated with an increased risk for vascular diseases. Inflammatory cytokines regulate PAI-1 through a hitherto unclear mechanism. Using reporter gene analysis, we could identify a region in the PAI-1 promoter that contributes to basal expression as well as to tumor necrosis factor α (TNFα) induction of PAI-1 in endothelial cells. Using this region as bait in a genetic screen, we could identify Nur77 (NAK-1, TR3, NR4A1) as an inducible DNA-binding protein that binds specifically to the PAI-1 promoter. Nur77 drives transcription of PAI-1 through direct binding to an NGFI-B responsive element (NBRE), indicating monomeric binding and a ligand-independent mechanism. Nur77, itself, is transcriptionally up-regulated by TNFα. High expression levels of Nur77 and its colocalization with PAI-1 in atherosclerotic tissues indicate that the described mechanism for PAI-1 regulation may also be operative in vivo.
1 September 1995 in Biochemical and Biophysical Research Communications